Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: An observational study

Annals of Pharmacotherapy

Volumn 35, Issue 1, 2001, Pages 14-20

  McCune, Jeannine S ^a   Oertel, Maryann D ^b   Pfeifer, Dennis ^b   Houston, Shelly A ^c   Bingham, Andrea ^b   Sawyer, William T ^d   Lindley, Celeste M ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IQVIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiemetic guidelines; Chemotherapy; Granisetron; Ondansetron

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; GRANISETRON; LORAZEPAM; ONDANSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CHILD; CONSTIPATION; DIARRHEA; DRUG COST; DRUG EFFICACY; EVALUATION; FEMALE; HEADACHE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NAUSEA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIEMETICS; CHILD; CONSTIPATION; DIARRHEA; DRUG THERAPY; DRUG UTILIZATION REVIEW; FEMALE; GRANISETRON; GUIDELINE ADHERENCE; HEADACHE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; ONDANSETRON; ORGANIZATIONAL POLICY; TREATMENT OUTCOME;

EID: 0035100667     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10014     Document Type: Article

References (19)

1. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993
2. Quality of life consequences of chemotherapy-induced emesis
3. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology
4. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting
5. Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center
6. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen
7. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population
8. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial
9. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference. The Granisetron Study Group
10. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group
11. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - A randomised study
12. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group
13. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients
14. Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group
15. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: A dose-ranging study
16. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
17. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study
18. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers
19. Pharmacist development and use of antiemetic protocols